DelMar Pharmaceuticals, Inc. announced that the board of directors has appointed Saiid Zarrabian as the full-time President and Chief Executive Officer of the Company, effective immediately. Mr. Zarrabian had previously served as the Company's interim President and Chief Executive Officer since November 2017 and prior to that as an independent board member since July 2017.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.1493 USD | -4.05% | -1.32% | -11.97% |
Apr. 03 | Sector Update: Health Care Stocks Softer Late Afternoon | MT |
Apr. 03 | Sector Update: Health Care | MT |
1st Jan change | Capi. | |
---|---|---|
-11.97% | 8.26M | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- KTRA Stock
- News Kintara Therapeutics, Inc.
- DelMar Appoints Saiid Zarrabian to Full-Time President and CEO